监禁史与注射吸毒者HIV和丙型肝炎病毒感染风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入已发表20项研究及未发表21项研究,评估注射吸毒者监禁史与HIV或HCV感染风险的关系。监禁可能显著驱动注射吸毒者中HIV和HCV传播。
要点
- 近期监禁使注射吸毒者HIV感染风险增加81%,HCV感染风险增加62%。
- 既往监禁与HCV感染风险增加21%相关,与HIV关联无统计学意义。
- 需针对监禁相关结构风险开发干预措施以降低HIV和HCV感染风险。
核心结论
- 监禁与注射吸毒者HIV和HCV感染风险短期显著增加相关,可能是HIV和HCV传播的重要驱动因素。
- 研究结果支持开发新干预措施以降低HCV和HIV感染风险,包括应对毒品法律和过度监禁带来的结构风险。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和PsycINFO数据库2000年1月1日至2017年6月13日发表的所有语言研究。
- 纳入测量社区招募注射吸毒者HIV或HCV发病率的原始研究,排除通过自我报告评估新发感染的研究。
- 共纳入20项已发表研究和21项未发表研究,来自大洋洲、西欧和东欧、北美和拉丁美洲、东亚和东南亚。
- 使用随机效应荟萃分析合并数据,采用Newcastle-Ottawa量表评估偏倚风险,用I2统计量和异质性P值评估研究间异质性。
临床怎么用
- 对注射吸毒者应询问近期和既往监禁史,以识别HIV和HCV感染高风险人群。
- 在监禁前后及释放后应加强HIV和HCV检测与预防干预,降低感染获得风险。
- 临床和公共卫生干预需关注毒品法律和过度监禁等结构因素对感染风险的影响。
局限性
- 仅纳入报告原始结果且非自我报告新发感染的研究,可能遗漏部分相关数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People who inject drugs (PWID) experience a high prevalence of incarceration and might be at high risk of HIV and hepatitis C virus (HCV) infection during or after incarceration. We aimed to assess whether incarceration history elevates HIV or HCV acquisition risk among PWID. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, and PsycINFO databases for studies in any language published from Jan 1, 2000 until June 13, 2017 assessing HIV or HCV incidence among PWID. We included studies that measured HIV or HCV incidence among community-recruited PWID. We included only studies reporting original results and excluded studies that evaluated incident infections by self-report. We contacted authors of cohort studies that met the inclusion or exclusion criteria, but that did not report on the outcomes of interest, to request data. We extracted and pooled data from the included studies using random-effects meta-analyses to quantify the associations between recent (past 3, 6, or 12 months or since last follow-up) or past incarceration and HIV or HCV acquisition (primary infection or reinfection) risk among PWID. We assessed the risk of bias of included studies using the Newcastle-Ottawa Scale. Between-study heterogeneity was evaluated using the I2 statistic and the P-value for heterogeneity. FINDINGS: We included published results from 20 studies and unpublished results from 21 studies. These studies originated from Australasia, western and eastern Europe, North and Latin America, and east and southeast Asia. Recent incarceration was associated with an 81% (relative risk [RR] 1·81, 95% CI 1·40-2·34) increase in HIV acquisition risk, with moderate heterogeneity between studies (I2=63·5%; p=0·001), and a 62% (RR 1·62, 95% CI 1·28-2·05) increase in HCV acquisition risk, also with moderate heterogeneity between studies (I2=57·3%; p=0·002). Past incarceration was associated with a 25% increase in HIV (RR 1·25, 95% CI 0·94-1·65) and a 21% increase in HCV (1·21, 1·02-1·43) acquisition risk. INTERPRETATION: Incarceration is associated with substantial short-term increases in HIV and HCV acquisition risk among PWID and could be a significant driver of HCV and HIV transmission among PWID. These findings support the need for developing novel interventions to minimise the risk of HCV and HIV acquisition, including addressing structural risks associated with drug laws and excessive incarceration of PWID. FUNDING: Engineering and Physical Sciences Research Council, National Institute for Health Research, National Institutes of Health.
引用
- Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018. PMID: 30385157. doi:10.1016/S1473-3099(18)30469-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。